Health Condition 1: K522- Allergic and dietetic gastroenteritis and colitis Health Condition 2: K522- Allergic and dietetic gastroenteritis and colitis Health Condition 3: K900- Celiac disease Health Condition 4: K508- Crohns disease of both small andlarge intestine Health Condition 5: K509- Crohns disease, unspecified Health Condition 6: K929- Disease of digestive system, unspecified Health Condition 7: K591- Functional diarrhea Health Condition 8: K520- Gastroenteritis and colitis due toradiat
Conditions
Interventions
Intervention1: Bifidobacterium breve,Bifidobacterium longum,Bifidobacterium infantis,Lactobacillus acidophilus,Lactobacillus plantarum,Lactobacillus paracasei,Lactobacillus bulgaricus,Streptococcus th
if not recovered then for 15 days
Control Intervention1: Bifidobacterium breve,Bifidobacterium longum,Bifidobacterium infantis,Lactobacillus acidophilus,Lactobacillus plantarum,Lactobacillus paracasei
if not recovered then for 15 days
Sponsors
Smt Kashibai Navale Medical College General Hospital
Eligibility
Inclusion criteria
Inclusion criteria: 1) Both males and females fulfilling definition criteria of chronic diarrhea i.e. three or more loose or watery stools daily lasting for four or more weeks 2) All participants accepting the provided written informed consent
Exclusion criteria
Exclusion criteria: 1) Previous abdominal surgery except appendectomy, caesarean section, tubal ligation, abdominal wall hernia repair or laparoscopic cholecystectomy; 2) Current use of medications that may alter gastrointestinal motility; 3) Over-the-counter medication use (other than those specifically screened by the investigator) within 3 days of transit studies; 4) Immuno deficient patients (including HIV positive) 5) Antibiotic use within 2 weeks prior to the 2-week run-in period; 6) Non consenting patients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1)To investigate the effects of probiotic enema formulations on gastrointestinal transit and symptoms (Clinical remission defined as clinical daily frequency of stool 3) of patients with chronic diarrhea within study period (Five Days)Timepoint: Day 5 | — |
Secondary
| Measure | Time frame |
|---|---|
| To investigate the effects of probiotic enema formulations on gastrointestinal transit and symptoms (Clinical remission defined as clinical daily frequency of stool 3) of patients with chronic diarrhea after study period during follow up (after fifteen days) Timepoint: Day 15 | — |
Countries
India
Contacts
Public ContactDr Jayprakash D Shirpurwar
Smt Kashibai Navale Medical College and General Hospital, Pune
Outcome results
None listed